Karl-Norbert Klotz spends much of his time researching Receptor, Adenosine receptor, Adenosine, Biochemistry and Adenosine A1 receptor. Many of his studies on Receptor apply to Stereochemistry as well. His studies deal with areas such as Endocrinology and Pharmacology as well as Adenosine receptor.
His study in Adenosine is interdisciplinary in nature, drawing from both Cell, Cancer research, Cyclase, Signal transduction and Adenosine receptor antagonist. Biochemistry connects with themes related to Transfection in his study. His Adenosine A1 receptor research is multidisciplinary, relying on both Molecular biology, Cell cycle and Growth factor receptor.
His primary areas of study are Adenosine receptor, Receptor, Stereochemistry, Adenosine and Biochemistry. His Adenosine receptor study combines topics in areas such as Adenylyl cyclase and Pharmacology. His Receptor research incorporates elements of Signal transduction and Binding site.
He interconnects Structure–activity relationship and Chemical synthesis in the investigation of issues within Stereochemistry. His work in Adenosine tackles topics such as Adenosine A3 receptor which are related to areas like Purinergic signalling. The concepts of his Agonist study are interwoven with issues in Antagonist and Ligand.
His primary scientific interests are in Adenosine receptor, Receptor, Stereochemistry, Adenosine and Pharmacology. Karl-Norbert Klotz has researched Adenosine receptor in several fields, including Antagonist, Molecular model, Docking and Xanthine. His Receptor study introduces a deeper knowledge of Biochemistry.
His research in Biochemistry intersects with topics in Chalcone and Pathogenesis. His Adenosine research is multidisciplinary, incorporating perspectives in Platelet activation, Platelet, Adenosine A1 receptor and Nucleoside. His studies in Pharmacology integrate themes in fields like In vitro, Agonist, Partial agonist, Parkinson's disease and Dopamine.
Karl-Norbert Klotz mainly focuses on Adenosine receptor, Adenosine, Stereochemistry, Pharmacology and Ring. His work deals with themes such as Docking and Ligand, which intersect with Adenosine receptor. His studies deal with areas such as Receptor, G protein-coupled receptor, Allosteric regulation, Partial agonist and Tachyphylaxis as well as Adenosine.
His study in Receptor is interdisciplinary in nature, drawing from both Substantia nigra, Neuropathic pain, Dopamine and Medicinal chemistry. His Pharmacology research is multidisciplinary, incorporating elements of Agonist, Dopaminergic, Antagonist, Parkinson's disease and Ischemia. His biological study spans a wide range of topics, including Molecular model and Formalin Test.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Bertil B. Fredholm;Adriaan P. IJzerman;Kenneth A. Jacobson;Karl-Norbert Klotz.
Pharmacological Reviews (2001)
Comparative pharmacology of human adenosine receptor subtypes – characterization of stably transfected receptors in CHO cells
C. Hoffmann;M. R. Leitz;S. Oberdorf-Maass;M. J. Lohse.
Naunyn-schmiedebergs Archives of Pharmacology (1997)
8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)--a selective high affinity antagonist radioligand for A1 adenosine receptors.
Martin J. Lohse;Karl-Norbert Klotz;Jutta Lindenborn-Fotinos;Martin Reddington.
Naunyn-schmiedebergs Archives of Pharmacology (1987)
Adenosine receptors and their ligands.
Naunyn-schmiedebergs Archives of Pharmacology (2000)
Analysis of receptor oligomerization by FRAP microscopy.
Sandra Dorsch;Karl-Norbert Klotz;Stefan Engelhardt;Martin J Lohse.
Nature Methods (2009)
2-Chloro-N6-cyclopentyladenosine: a highly selective agonist at A1 adenosine receptors.
Martin J. Lohse;Karl-Norbert Klotz;Ulrich Schwabe;Gloria Cristalli.
Naunyn-schmiedebergs Archives of Pharmacology (1988)
Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A2A-Selective adenosine receptor antagonists
Roland Sauer;Juris Maurinsh;Ulrike Reith;Friederike Fülle.
Journal of Medicinal Chemistry (2000)
The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion.
Michael P. Schön;Margarete Schön;Karl-Norbert Klotz.
Journal of Investigative Dermatology (2006)
Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity
Sebastian F. M. Häusler;Itsaso Montalbán del Barrio;Jenny Strohschein;P. Anoop Chandran.
Cancer Immunology, Immunotherapy (2011)
[(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors.
Katia Varani;Stefania Merighi;Stefania Gessi;Karl-Norbert Klotz.
Molecular Pharmacology (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: